Pan Cancer T B.V.

AktivHealthTechRotterdam, NLGegr. 2020Website

Pan Cancer T B.V. is a biotechnology company based in Rotterdam, Netherlands, specializing in the development of TCR-T cell therapies for hard-to-treat solid tumors. Founded in 2020 as a spin-off of Erasmus MC, the company focuses on identifying unique tumor targets expressed across multiple solid cancers and developing proprietary technologies to improve T cell persistence. Its lead program, PCT1:CO-STIM, targets the ROPN1 protein, expressed in over 90% of triple-negative breast cancer and melanoma cases, aiming to overcome immune resistance in solid tumors and provide durable responses for patients with limited treatment options.